Shandong Xinhua (00719) has received the National Medical Products Administration's approval for the issuance of cobamamide tablets "Drug Supplement Application Approval Letter".

SHANDONG XINHUA (00719) announced that, recently, the company received the approval notice for a supplementary drug application for methylcobalamin tablets (hereinafter referred to as "the product") issued by the National Medical Products Administration. The approval allows the transfer of the supplementary application for the product. The announcement stated that the methylcobalamin tablets were approved by the National Medical Products Administration in April 2025, and Shandong Xinhua Pharmaceutical became the holder of the product's marketing authorization. The launch of this product will enrich the company's neurology drug product line and enhance the company's overall competitive advantage.